While risks to the stock still remain, UBS has upgraded Biogen Inc BIIB 0.88% from Sell to Neutral and has raised its price target for the stock from $262 to $270. At this point, the risks are fully priced into the stock, analyst Carter Gould wrote on Monday.
“In our view, the competitive threat to Biogen’s Spinraza (in Type I SMA patients) from gene therapy is now priced in and sentiment is near a bottom following the CFO’s recent departure,” Gould wrote.
In addition, Phase 3 dosing changes reflect confidence in aducanumab’s safety, and UBS now anticipates Biogen will release interim data on the study in 2018.
Overall, UBS doesn’t see Biogen’s multiple sclerosis business as a major driver for the stock considering the increasingly competitive environment. In addition, generic competition will certainly come into play in the longer-term. Still, the risks associated with the MS business are offset by Biogens increasing focus on aducanumab, Gould wrote.
Looking ahead to Biogen’s Q2 earnings call, UBS is anticipating strong numbers from Spinraza, an update on a challenging MS market and details on the company’s strategic review. Gouldsaid the strategic review update could be a great opportunity for the company to increase investor focus on aducanumab and highlight the potential positives associated with the dosage change.
UBS has raised its probability of success for aducanumab to 40 percent, which is still well below its typical 70-75 percent range for Phase III assets. However, the change in success probability has raised…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
